A detailed structural and functional analysis of VHL mutations and their effects on hypoxia inducible factor-α in sporadic clear cell renal carcinoma
SETD2, a histone methyltransferase, is misregulated in advanced clear cell renal cell carcinoma (ccRCC)
Serum proteomics classifies outcome in renal cell carcinoma (RCC) patients receiving sunitinib and erlotinib
Impact of targeted therapy on overall survival in advanced kidney cancer; a population based analysis of the national Surveillance Epidemiology and End Results (SEER) registry database
Quantitative gene expression using RT-PCR refines the prediction of recurrence risk in resected T1 clear cell renal cell carcinoma (ccRCC)
Real-world presurgical characteristics and postsurgical morbidity of 10,404 Americans undergoing nephrectomy because of renal tumors
Type 1 cytokine response and myeloid derived suppressor cells (MDSC) in patients with metastatic renal cell carcinoma (mRCC) with pazopanib or temsirolimus treatment
Anti-tumor activity observed in an ongoing phase 1 drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma
Subgroup analysis of the phase 3 RECORD-1 trial of everolimus in patients with metastatic renal cell carcinoma: 1 versus 2 prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies
‘Real World’ treatment of metastatic renal cell carcinoma (mRCC) in community and academic settings
A pooled analysis of the efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma (mRCC)
Clinicopathological feature of T1a renal cell carcinoma
The renal nephrometry scoring system is predictive of partial nephrectomy complexity
Impact of tumour size on metastases and locally advanced growth in renal cell carcinoma up to 7 cm
Decreased incidence of renal cell carcinoma in Sweden 1980-2000
A multicenter, open-label, randomized phase 3 trial comparing the safety and efficacy of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies
Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (LT-OS) with sunitinib in 1,059 patients, treated on clinical trials, with metastatic renal cell carcinoma (mRCC)
Final analysis of the phase 2 randomized discontinuation trial of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma
Relationship between Karnofsky Performance Status (KPS) and tumor response: analysis of the RECORD-1 phase 3 trial of everolimus in patients with advanced renal cell carcinoma (RCC)
The role of Src kinase in renal cell cancer
NOTE: TRIALS IN PROGRESS SUBMISSION EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a SWOG III Adjuvant Study (S0931)
Phase 1 trial of tivozanib (AV-951) combined with temsirolimus in patients with renal cell carcinoma
A dynamic tumor model of the RECORD-1 phase 3 trial in patients with metastatic renal cell carcinoma (mRCC): quantification of the effect of everolimus on tumor growth and new metastases
Glycogen provides nutritional support to renal cancer cells under conditions of stress and may serve as a marker of response to anti-angiogenic therapy with bevacizumab
Effects of fibroblast growth factor on the angiogenesis and proliferation of human renal cancer cells
Practice-setting and surgeon characteristics heavily influence the decision to perform partial nephrectomy among AUA surgeons
Trade-offs between toxicity and progression-free survival in renal cell carcinoma therapies: a choice-format conjoint study of patient preferences
Comparison of hilar clamping and non-hilar clamping partial nephrectomy for tumors involving a solitary kidney
Management of renal masses during pregnancy: the role of partial nephrectomy
Conservative management of urinary fistulae after open partial nephrectomy for renal cortical masses